Payment momentum meets oncology-AI arms race
ONE BIG THING
Medicare moves from rhetoric to rules on imaging-AI payment
Draft legislative language circulating in both the House and Senate directs CMS to publish a transitional payment framework for FDA-cleared imaging algorithms within 12 months. The aim is to define a temporary coding and reimbursement structure so hospitals and outpatient centers can more reliably budget AI solutions.
Marketstrat’s internal modeling suggests that even a modest $28 per-scan reimbursement rate for AI-based CT triage could yield roughly $450 million in first-year U.S. spend. Under that scenario, hospitals could see their AI solutions pay back in as little as 14 months, down from the current two to three years—primarily driven by faster patient throughput, fewer diagnostic errors, and reduced readmission penalties.
Why it matters: This signals the pivot point where AI transitions from a pilot-friendly “nice to have” to a reimbursable, revenue-recognized investment. Vendors with robust clinical validation and well-structured ROI messaging stand to gain immediate traction. Providers facing margin pressures are eyeing AI to cut overhead, expedite patient flow, and reduce missed diagnoses.
DEEPER DIVES
Below, we highlight four key areas shaping this week’s market narrative. From new policy mandates to capital moves and cutting-edge product unveilings, each development underscores how AI is gaining ground in healthcare’s operational and strategic planning.
1 | Policy & Reimbursement — “Code or be coded out”
In healthcare, policy often decides winners and losers by setting payment levels and usage rules. As AI gains clinical acceptance, the legislative environment is racing to keep up. Here’s the quick breakdown of what’s happening and how it may unfold over the next year:
| What’s new | Short-term impact | 12-mo outlook |
|---|---|---|
| Congress sets a payment deadline | Hospital CFOs are revisiting AI business plans; imaging directors are rethinking budgets | A new CMS rule (potentially in Q1 2026) likely attaches reimbursement to proven clinical outcomes |
| CMS MA 2026 final rule cautions against “AI-only” prior auth | Creates stricter guardrails, rewarding transparent AI that includes human oversight | Payers may insist on prospective real-world evidence before adopting CPT Category I codes |
| Private payers pilot bundled AI fees | Preliminary data suggests a 5–7% net cost savings for acute stroke pathways | Some commercial payers could leapfrog CMS by offering more comprehensive outpatient imaging coverage |
Context & Analysis:
- Balancing speed and safety: Legislators and payers want to encourage innovation but remain cautious about “black box” algorithms that might lead to unintended consequences.
- Outcome-based tilt: Expect any future payment to hinge on real-world performance data—potentially tying incremental fees to documented time savings, error reduction, or net cost offsets.
- Provider readiness: Many hospitals are still uncertain about how to fully integrate AI into existing workflows. A transitional payment code could push them off the fence, accelerating adoption if the ROI is evident.
Marketstrat’s Take:
Providers should plan for more rigorous AI validation demands. We anticipate hospital executives will require robust pilot data that ties each algorithm to a financial upside, such as better staff productivity or reduced readmissions, to secure AI line items in 2026 budgets.
2 | Stroke AI
The bipartisan “Medicare AI Payment Act of 2025”—dropped in both chambers on 11 Apr—gives CMS 12 months to stand up a national payment pathway for FDA-cleared algorithms, starting with radiology triage/detection tools.
Marketstrat’s Take:
A dedicated payment stream would blow oxygen onto a smoldering market. At today’s average licence of ≈ $55 k/site/yr (stroke-triage AI, Marketstrat model), U.S. hospitals buy mainly where NTAP offsets costs. If CMS pays $28/case (parity with CAD-mammography), stroke & trauma CT volumes alone (~16 M annually) translate to a $450 M reimbursable pool—3× current spend.
3 | Product & Tech — “Oncology workflows go MR and AI”
The oncology space is emerging as a hotspot for advanced imaging and AI. Providers are seeking ways to improve speed, precision, and patient comfort in radiotherapy (RT) planning—a domain where minute details can drastically alter outcomes.
GE HealthCare @ ESTRO 2025
GE took center stage at the recent European Society for Radiotherapy & Oncology (ESTRO) annual meeting, unveiling a suite of solutions designed to integrate magnetic resonance imaging (MRI) seamlessly into RT workflows.
| Module | Unlock | Workflow gain (Marketstrat field test) |
|---|---|---|
| Spectronic Medical MRI Planner | Generates synthetic CT scans from MR data | Eliminates the need for a separate CT; saves ~18 mins in the planning step |
| MR Contour DL™ | Auto-segments 37 organs-at-risk | Reduces manual contouring time by ~70% |
| iRT 2.0 Orchestrator | Plug-and-play integration for third-party AI tools | Provides a single command dashboard, cutting up to 1–2 days off new app activation |
Competitive Watch:
- Siemens-Varian is expected to respond with an upgrade to Eclipse/RT-Digitizer this summer, which may also feature robust MR-contouring modules.
- Elekta is currently beta-testing an MR-first pipeline with Philips, hinting at an industry-wide shift to MRI-centered planning.
Why It Matters:
- MR-first approach: Reduced radiation exposure for the patient and clearer soft tissue definition enable more targeted therapy with fewer side effects.
- Workflow synergy: Automated organ contouring and AI-driven radiotherapy planning can significantly shrink waiting times, potentially allowing more patients to be treated each day.
- Profitability levers: As RT centers squeeze more treatments into the same operating window, revenue per machine could climb.
4 | Capital & M&A — “Therapeutic-ultrasound valuation shock”
Healthcare investors are still flush with capital, but they’re increasingly choosy. The big story of the week: a potentially eye-popping valuation in the therapeutic-ultrasound space.
- HistoSonics is reported to be in a sale process that might top $2.5 billion, implying a valuation multiple of roughly 25× projected 2025 revenues. This signals that hospital-friendly, non-invasive treatments are attracting a premium.
- Private equity continues to roll up imaging and RT clinic networks. The latest transaction: Basel Medical acquiring Bethesda Imaging, adding 22 outpatient sites across three states to its growing portfolio. The consolidation trend aims to negotiate better deals with payers and invest in upgrades—often including AI.
- Venture deal flow in imaging AI remains flat year-to-date, following a 48% drop in 2024. While early-stage seed rounds are still finding backers, Series B or later typically come with stricter clinical milestones tied to funds release.
Strategic Angle:
- Exits remain strong for innovative hardware platforms that can demonstrate clinical traction and a large total addressable market (TAM).
- Consolidation wave in outpatient imaging could catalyze a broader push for AI standardization, as private equity firms often seek to scale best practices across newly acquired sites.
- Growth capital is selective. Companies hoping to raise bigger rounds should come prepared with real-world performance data and a path to immediate financial return for customers.
5 | Market Data Spotlight — Oncology AI moving from “niche” to “platform”
- Clinical proof tipping point. Prospective trials (e.g., MASAI, NELSON) cement AI’s value in breast and lung screening, pushing payors toward coverage pilots.
- OEM pull-through. GE HealthCare, Siemens, and Fujifilm now bundle FDA-cleared algorithms with mammography and CT systems, compressing standalone vendor margins but accelerating unit penetration.
- Regional fast followers. Korean, Chinese, and Israeli startups are expanding beyond home markets, intensifying price competition in APAC and EMEA.
- Capital outlook. Oncology AI drew US $540 M in new funding during 2023-24—half of all imaging-AI venture dollars—keeping Rising Stars well-financed for global expansion.
Marketstrat’s internal estimates highlight steady growth in overall medical imaging and a faster acceleration in AI-driven segments. The shift from R&D curiosity to tangible business case is transforming these predictions into boardroom must-haves.
Key Takeaway:
We anticipate oncology imaging AI evolving into end-to-end solutions that connect screening, diagnosis, and therapy planning. Companies able to integrate “radiomics + pathology + genomics” could differentiate themselves. From a Marketstrat vantage, we advise vendors and providers to build clinical proof around mortality reductions and cost savings, especially for top high-incidence cancers like breast, lung, and colorectal. Access to large databases and robust multicenter trials will be key to further regulatory endorsements and broad adoption.
MARKETSTRAT POV
Payment clarity for AI is no longer a distant hope; it’s entering the realm of near-term inevitability. Hospitals and imaging centers that move early to integrate validated AI tools could reap operational and financial rewards—especially as labor shortages persist and payers push for real-world performance metrics.
Looking ahead, the oncology sector stands to benefit most from AI that cuts down planning time and improves therapy targeting. Meanwhile, any new payment framework from CMS or commercial insurers will likely drive a flurry of pilot-to-scale transitions. The key success factor will be clinical ROI: solutions must show not only improved quality of care but also quantifiable time or cost savings.
Our Advice to Vendors: Bolster your evidence base. Prepare to pivot from neat technology demos to robust, multi-center data that proves consistent efficacy. If you haven’t built relationships with payers yet, start now—anticipating the proof points they’ll ask for when drafting coverage policies.
Our Advice to Providers: Don’t wait for final rules to be published. Initiate small pilot programs, gather internal metrics, and refine AI workflows. When the transitional payment arrives, you’ll have the best vantage to roll out quickly and capture the first wave of reimbursement benefits.
QUICK-GLANCE GRID — 20 HEADLINES THIS WEEK
A snapshot of top developments shaping the imaging, radiotherapy, and digital health landscape. Use this grid as your at-a-glance update for deals, approvals, and new prototypes.
| Theme | Event | Why it matters |
|---|---|---|
| Payment | Medicare AI Payment Act draft sets a 12-month clock | Formalizes the path from pilot testing to full budget allocations |
| Regulation | CMS MA final rule presses for stronger clinical evidence | Aims to rein in black-box algorithms for prior authorization |
| FDA | MR Contour DL™ cleared (GE) | Marks first deep-learning auto-segmentation for MR-only RT |
| FDA | Clarius Handheld Prostate-AI cleared | Expands AI to point-of-care urology exams |
| FDA | Brainomix e-Stroke Core approved | Adds ischemic-core quantification to large-vessel-occlusion triage |
| FDA | HeartFocus Echo-AI cleared | Helps non-experts acquire and interpret cardiac ultrasound |
| Funding | Chipiron raises €14 M for 0.2T MRI | Accelerates low-field MRI access in resource-limited settings |
| Funding | Gestalt Dx nets $7.5 M for digital pathology | Shows cross-modality AI demand remains strong |
| M&A | HistoSonics sale rumors at $2.5 B | Illustrates high valuation multiples in non-invasive therapies |
| M&A | Basel Medical buys Bethesda Imaging | Continues private equity clinic consolidation trend |
| OEM | GE oncology-AI trio at ESTRO | Emphasizes an MR-first strategy for improved RT workflows |
| OEM | Canon touts photon-counting CT prototype | Increases competition for next-gen CT modality replacement |
| Sci-Tech | Lunit multi-cancer pathology demo | Brings AI into biomarker discovery, bridging diagnostics & pharma |
| Clinical | JAMA study: AI slashes trial screening time by 22% | Potentially accelerates oncology drug trials & recruitment |
| Conference | ESTRO panels on LLM-driven dose planning | Signals a push toward next-gen RT automation leveraging AI models |
| Policy | AdvaMed releases AI evidence roadmap | Lobbying for tiered reimbursement codes to incentivize validated AI |
| Operations | US Radiology to open 12 de-novo sites | Demonstrates continued outpatient imaging growth, fueling AI adoption |
| Security | FTC probes data-sharing in imaging-AI apps | Could raise compliance costs and slow smaller AI vendors |
| Workforce | RSNA survey: AI usage at 38% daily (up from 23% in 2022) | Signals mainstreaming of AI in radiologist workflows |
| Education | ACR launches AI credential for technologists | Aims to build an up-skilled workforce for advanced imaging tasks |
Sources: All figures, insights, and commentary in this issue of Markintel Pulse draw on Marketstrat’s proprietary research, public regulatory filings (FDA, CMS, EMA), company press releases and earnings calls, peer-reviewed journals, and leading industry conferences held through [Week Ending 2 May 2025]. While Marketstrat verifies all information for accuracy and relevance, final interpretations reflect Marketstrat’s independent analysis.
FAQs — Imaging-AI Payment & Oncology Automation (May 2025)
Q1. What is the proposed Medicare payment for FDA-cleared imaging-AI algorithms?
A bipartisan bill introduced on 11 Apr 2025 directs CMS to set a dedicated payment—modeled around $28 per outpatient CT study—within 12 months.
Q2. How does that payment compare to today’s NTAP add-on?
NTAP currently covers up to $1,000 per Medicare inpatient stroke case. The new outpatient fee would extend reimbursement to the much larger ambulatory volume.
Q3. What return on investment (ROI) can hospitals expect from stroke-triage AI?
In a mid-size Primary Stroke Center (≈ 800 head-CTs/year), licence cost is repaid in < 14 months, delivering a 2.8 × annual ROI when NTAP, the proposed outpatient fee, and reduced readmissions are combined.
Q4. Why is GE HealthCare’s new MRI-only radiation-therapy suite important?
By converting standard MR images into synthetic CT and auto-segmenting 37 organs-at-risk, GE’s workflow cuts planning time 70 %, paving the way for faster, more precise cancer treatment.
Q5. How big is the global market for imaging-AI software?
Marketstrat values the full-stack imaging-AI market at $3.9 B in 2024, projecting $21.6 B by 2030 (32 % CAGR).
Q6. Which modalities are growing fastest?
Stroke & neuro-AI lead with ~39 % CAGR, followed by breast-imaging AI at ~28 %, driven by digital breast tomosynthesis adoption and value-based payment incentives.
Q7. What evidence will payers demand before covering AI tools?
Expect payers to require multi-center prospective studies, real-world utility data, and transparent algorithm performance across diverse patient populations.
Q8. Where can I get deeper analysis?
Subscribe to Marketstrat’s Markintel Pulse or contact us for custom briefings on imaging-AI economics and oncology-workflow automation.
About Marketstrat™
Marketstrat™ is a market intelligence and GTM enablement firm committed to empowering clients in data-driven industries. Under the Markintel™ brand, it delivers robust market intelligence, while GrowthEngine™ solutions offer specialized GTM advisory and app-based tools—together fueling growth, innovation, and competitive advantage. For more information, visit www.marketstrat.com.
Marketstrat™, Markintel™, and GrowthEngine™ are pending trademarks of Marketstrat, awaiting final registration.
- Check out our collection of Markintel Horizon and Markintel Pulse research.
- Check out details on our upcoming report, World Market for AI in Medical Imaging
- Check out free Research and Insights and Analysis of Industry Events
